• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4640408)   Today's Articles (207)   Subscriber (50363)
For: Adair CG, Bridges JM, Desai ZR. Renal function in the elimination of oral melphalan in patients with multiple myeloma. Cancer Chemother Pharmacol 1986;17:185-8. [PMID: 3719900 DOI: 10.1007/bf00306752] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Number Cited by Other Article(s)
1
Nooka AK, Harvey RD, Langston A, Collins H, Lonial S, Kaufman JL. Optimal Dosing of Melphalan As High-Dose Therapy Before Autologous Hematopoietic Stem Cell Transplantation in Myeloma Patients With Solitary Kidney: A Case Series. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 2014;14:e59-63. [DOI: 10.1016/j.clml.2013.11.007] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/24/2013] [Accepted: 11/05/2013] [Indexed: 12/21/2022]
2
Development and validation of LC–MS/MS assays for the quantification of bendamustine and its metabolites in human plasma and urine. J Chromatogr B Analyt Technol Biomed Life Sci 2012;893-894:92-100. [DOI: 10.1016/j.jchromb.2012.02.039] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2011] [Revised: 02/16/2012] [Accepted: 02/23/2012] [Indexed: 11/21/2022]
3
Feliz V, Saiyad S, Ramarao SM, Khan H, Leonelli F, Guglin M. Melphalan-induced supraventricular tachycardia: incidence and risk factors. Clin Cardiol 2011;34:356-9. [PMID: 21538392 DOI: 10.1002/clc.20904] [Citation(s) in RCA: 66] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/20/2010] [Accepted: 01/30/2011] [Indexed: 12/22/2022]  Open
4
Kühne A, Kaiser R, Schirmer M, Heider U, Muhlke S, Niere W, Overbeck T, Hohloch K, Trümper L, Sezer O, Brockmöller J. Genetic polymorphisms in the amino acid transporters LAT1 and LAT2 in relation to the pharmacokinetics and side effects of melphalan. Pharmacogenet Genomics 2007;17:505-17. [PMID: 17558306 DOI: 10.1097/fpc.0b013e3280ea77cd] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
5
Grazziutti ML, Dong L, Miceli MH, Krishna SG, Kiwan E, Syed N, Fassas A, van Rhee F, Klaus H, Barlogie B, Anaissie EJ. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model. Bone Marrow Transplant 2006;38:501-6. [PMID: 16980998 DOI: 10.1038/sj.bmt.1705471] [Citation(s) in RCA: 75] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
6
Desoize B, Robert J. Individual dose adaptation of anticancer drugs. Eur J Cancer 1994;30A:844-51. [PMID: 7917547 DOI: 10.1016/0959-8049(94)90304-2] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
7
Reetze-Bonorden P, Böhler J, Keller E. Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations. Clin Pharmacokinet 1993;24:362-79. [PMID: 8504621 DOI: 10.2165/00003088-199324050-00002] [Citation(s) in RCA: 96] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
8
Smith DC, Jodrell DI, Egorin MJ, Ambinder RM, Zuhowski EG, Kreis W, Ellis PG, Trump DL. Phase II trial and pharmacokinetic assessment of intravenous melphalan in patients with advanced prostate cancer. Cancer Chemother Pharmacol 1993;31:363-8. [PMID: 7679331 DOI: 10.1007/bf00686149] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
9
Osterborg A, Ehrsson H, Eksborg S, Wallin I, Mellstedt H. Pharmacokinetics of oral melphalan in relation to renal function in multiple myeloma patients. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY 1989;25:899-903. [PMID: 2737222 DOI: 10.1016/0277-5379(89)90138-7] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
10
Friberg S, Ehrsson H, Eksborg S, Carenfeldt C. Intratumoral measurement and plasma pharmacokinetics of intravenously administered melphalan. Report of a patient with plasmacytoma. Cancer Chemother Pharmacol 1987;20:342-3. [PMID: 3690809 DOI: 10.1007/bf00262589] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
11
Wynne H, Woodhouse KW. The disposition of cytotoxic drugs in the elderly. BAILLIERE'S CLINICAL HAEMATOLOGY 1987;1:513-31. [PMID: 3322447 DOI: 10.1016/s0950-3536(87)80011-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA